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The novel discovery of the systemic role of vitamin D in the modulation of the immune system especially the Type 1 helper T cell
(Th1) pathway reveals its potential for treating Th1 inﬂammatory diseases. Psoriasishas been recently established to be a systemic
disease centered on inﬂammationand involvement ofcytokines of the Th1 pathway. There is an increased prevalence of metabolic
syndromeinpatientswithpsoriasis.Metabolicsyndromealsoinvolvesaproinﬂammatorystate.Thispaper proposestheideaofthe
potential use of oral vitamin D to treat psoriasisand metabolic syndrome concurrently. We propose there is merit in more clinical
trials investigating the use of vitamin D to treat both psoriasis and metabolic syndrome through its anti-inﬂammatory eﬀects. On
application to psoriasis management and prognosis,the goal is to decrease the risk for cardiovascular disease and decrease disease
morbidity and mortality.
1.Introduction
The recent discovery that vitamin D receptors are found
in most tissues and cells in the body opened a whole new
arena of research. Vitamin D can play a role in decreasing
the risk of many chronic illnesses, including autoimmune
diseases, infectious diseases, cardiovascular disease, and
common cancers such as colorectal, breast, and prostate
cancers. It speciﬁcally has a role in cellular proliferation,
diﬀerentiation, apoptosis, and angiogenesis [1]. Vitamin D
has been found to be an immune regulatory hormone with
beneﬁcial eﬀects on inﬂammatory diseases, mediated by
helper T-lymphocytes type 1 (Th1) cells [2, 3], such as
diabetes, psoriasis, Crohn’s disease, and multiple sclerosis
[1].
Psoriasis is a common Th1-mediated inﬂammatory
disease characterized by scaly plaques on the skin, which
can be painful and pruritic. It is also associated with
psoriaticarthritis, Crohn’s disease, diabetesmellitus(type2),
metabolic syndrome, depression, and cancer [4–6]. It aﬀects
1–3% of the general population [4, 5].
Controversy exists over the precise criteria for diagnosis
and classiﬁcation of metabolic syndrome; however, it is
accepted that it consists of a constellation of metabolic
abnormalities including glucose intolerance, insulin resis-
tance, central obesity, dyslipidemia, and hypertension [7].
Theprevalenceofmetabolicsyndromevariesgreatlybetween
populations and age groups ranging from 4% to 46% [8].
Metabolic syndrome is signiﬁcantly increased in patients
with psoriasis [9].
This paper strives to highlight the association between
psoriasis, metabolic syndrome, and vitamin D. In addition,
it proposes the hypothesis of potentially using oral systemic
vitamin D as a modality to treat psoriasis and metabolic
syndrome concurrently.
2.PsoriasisPathophysiology
Psoriasis was ﬁrst described as a disease that primar-
ily aﬀects epidermal keratinocyte proliferation and sec-
ondary cutaneous inﬂammatory inﬁltration [6]. In the last
decade it has become evident that psoriasis is a systemic2 Dermatology Research and Practice
immune-mediated inﬂammatory disease primarily involving
Th1 cells. Cytokines of the Th1 pathway (interferon-γ,
interleukin 2, interleukin 12, and TNF-α)p r e d o m i n a t ei n
psoriatic plaques. It is widely accepted that an unknown
stimulus activates cutaneous dendritic antigen-presenting
cells. These activated antigen-presenting cells then activate
helper T cells which lead to the subsequent release of a
cascade of inﬂammatory cytokines. This cascade results
in recruitment and activation of other cells types such
as endothelial cells and neutrophils, and production of
chemokines and growth factors. Eventually this leads to the
proliferation of keratinocytes. A chronic inﬂammatory state
then ensures and leads to the formation of psoriatic skin
lesions [4, 6]. Recently, Interleukin-17-secreting helper T
(Th17) cells have been identiﬁed to play an important role in
psoriasis pathogenesis. Interleukin-17 promotes inﬂamma-
tion by inducing the expression of chemoattractants that are
found in psoriatic lesions. Th17 cells also secrete interleukin
22, which is involved in keratinocyte diﬀerentiation retarda-
tion leading to keratinocyte proliferation [10].
3.Metabolic SyndromePathophysiology
Metabolic syndrome is accepted to be centered on insulin
resistance and obesity. Free fatty acids (FFA) are released
from abundant adipose tissue mass. FFA’s eﬀects on the liver
include production of glucose and triglycerides, and secre-
tionofvery low densitylipoproteins(VLDL)[7]. FFAinhibit
insulin-mediatedglucoseuptakeandthereforeleadtoinsulin
resistance. Increased circulating glucose and FFA increase
pancreatic secretion of insulin resulting in hyperinsulinemia
which can then increase sympathetic nervous system activity
and contribute to hypertension [7]. Adipose tissue also
contains cells such as adipocytes and monocyte-derived
macrophages. These cells contribute to the proinﬂammatory
statethroughthesecretionofinterleukin-6(IL-6)andTNF-α
amongothers[7].These inﬂammatory factorsleadtofurther
insulin resistance and lipolysis of adipose tissue triglyceride
stores and an additional increase in circulating FFA. There
are also reductions in the production of adiponectin which
is an anti-inﬂammatory and insulin sensitizing cytokine
[7, 11]. The most widely accepted criteria for metabolic
syndrome is by the National Cholesterol Education Program
Adult Treatment Panel III. The deﬁnition deﬁnes metabolic
syndrome as presence of at least three of the following:
abdominal obesity (waist circumference equal to or greater
than 102cm in men; 88cm in women), elevated serum
triglycerides (equal to or greater than 150mg/dL or drug
treatment for elevated levels), low HDL cholesterol (men
<40mg/dL;women<50mg/dL),andelevatedbloodpressure
(equal to or greater than 130/85mmHg or drug treatment
for hypertension), elevated fasting glucose (equal to or
greater than 110mg/dL). The World Health Organization
and the International Diabetes Foundation deﬁne metabolic
syndrome under similar parameters [12, 13].
4.Psoriasisand Metabolic Syndrome
The pathogenesis of psoriasis and metabolic syndrome both
involve inﬂammation. There is also evidence suggesting
that there is a genetic link. A number of genes such as
PSORS2, PSORS3, and PSORS4 are associated with psoriasis
susceptibility and are also associated with metabolic disease
[14]. Many studies have shown a link between psoriasis
and metabolic syndrome [14]. To highlight, Gisondi and
colleagues [9] established that there is a 30.1% prevalence
of metabolic syndrome in psoriatic patients compared to
20.6% in the control population (P = .005, OR: 1.65, 95%,
conﬁdence interval: 1.16–2.35).Sommer and colleagues [13]
reportedthatGerman patientshospitalizedforpsoriasis were
6-fold more likely to have metabolic syndrome compared
with control patients admitted for melanoma surgery. Few
studies have explored the possibility of treating psoriasis
by treating components of metabolic syndrome. Naldi and
colleagues [15] showed that in a large-scale cohort study of
2000 patients, obese patients had more severe psoriasis that
were more resistant to treatment compared to non obese
psoriatic patients. Hossler and colleagues [16]o b s e r v e dt w o
patients with body mass indices greater than 50kg/m2 who
had marked improvement in their psoriasis after gastric
bypass surgery and weight loss.
5.CardiovascularDisease Risk
Cardiovascular disease, like psoriasis and metabolic syn-
drome, also resultfrom a proinﬂammatory state. Endothelial
cells in atherosclerotic blood vessels facilitate the attachment
ofT-lymphocytes,theattractionofmastcells,and,asaresult,
the release of a cascade of proinﬂammatory cytokines such
as TNF-α is initiated. The proinﬂammatory state plays a
key role in fatty streak formation, plaque formation, and
eventually thrombosis [17]. Studieshave shown an increased
risk ofmyocardialinfarction (MI)andstrokeinpatientswith
psoriasis. Gelfand and colleagues [18] showed that 2.9% of
patients in the severe psoriasis group developed MIs while
only 2.0% of the control population developed MIs. Gelfand
and colleagues [19] also found that there is a 50% increase
in mortality in patients with severe psoriasis compared to
the control group. They found that patients with severe
psoriasis died 3.5(male) and 4.3(female) years youngerthan
patients without psoriasis. Mehta and colleagues [20]f o u n d
that patients with severe psoriasis have a clinically signiﬁcant
57% increased risk of cardiovascular death while adjusting
for conventional cardiovascular risk factors (history of MI,
stroke, transient ischemic attack, or atherosclerotic disease).
This suggests that psoriasis is an independent risk factor for
cardiovascular disease.
Similarly, patients with metabolic syndrome are also at
an increased risk for cardiovascular disease. Adipose tissue
overproduces plasminogen activator inhibitor-1 (PAI-1). In
addition, cytokines and FFA in metabolic syndrome also
increase the liver production of ﬁbrinogen and PAI-1. The
increase in PAI-1 and ﬁbrinogen results in a prothrombotic
state. Studies have shown increased risk for cardiovascular
disease and mortality in patients with metabolic syndrome
[21]. Isomaa and colleagues [22] found that subjects with
metabolic syndrome were at a three-fold increased risk for
developing coronary heart disease and stroke (P<. 001).
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patients with metabolic syndrome (12.0%) compared to
controls (2.2%; P<. 001). Lakka and colleagues [23]
reported that men with metabolic syndrome were 2.9–
4.2-times more likely to die from cardiovascular disease
compared to controls after adjustment for conventional
cardiovascular risk factors.
Therefore patients with both psoriasis and metabolic
syndrome are at a greatly increased risk for developing
cardiovascular disease.
6.VitaminDand Psoriasis
Vitamin D has been used to treat psoriasis in the topical
form with great success [24, 25]. 1-α, 25-dihydroxyvitamin
D3 (calcitriol) is the hormonally active form of Vitamin D.
It aﬀects cellular function by acting through the vitamin D
receptor (VDR) on keratinocytes [26, 27]. VDR binds to
and activates transcription of genes that inﬂuence growth,
diﬀerentiation,andinﬂammation inkeratinocytes.Calcitriol
has also been shown to have immunomodulatory eﬀects
on monocytes, macrophages, T cells, and dendritic cells
[26, 27]. It is believedthat through these mechanisms topical
Vitamin D actively treats psoriatic skin lesions. However, the
evidence that psoriasis is a systemic disease, which aﬀects
many organ systems, and involves many comorbidities,
namely,thecardiovascular systemsuggestsmerit inrevisiting
systemic oral vitamin D for treatment of the inﬂammatory
pathogenesis ofpsoriasis. At this point in time, there are very
fewstudiesthat haveinvestigated theuse oforalvitamin Din
patients with psoriasis. Perez and colleagues [28] established
that 88% of 85 psoriasis patients treated with oral vitamin
D had improvement in their psoriasis, 26.5% had complete
clearance, 36.2% had moderate improvement, and 25.3%
had slight improvement. An evaluation of serum calcium
concentrations and urinary calcium excretion and creatinine
clearance suggested that oral Vitamin D altered creatinine
metabolism or secretion but did not aﬀect renal function
[28]. Werner de Castro and colleagues [29] published the
only report to date of the resolution of anti-TNFα-induced
psoriasiform lesions (biopsy conﬁrmed) by doses of Vitamin
D3 in a patient with vitamin D deﬁciency and rheumatoid
arthritis. The recent discovery of the systemic role of vitamin
D suggests that there is great merit in revisiting the use of
system vitamin D to treat psoriasis with large scale clinical
trials to assess the safety and eﬃcacy. It would also be very
interesting and relevant to conduct studies looking at the
baseline serum vitamin D level in patients with psoriasis.
7.VitaminDand Metabolic Syndrome
Recent research suggests that vitamin D can improve
metabolic syndrome. Vitamin D has been proposed to be
sequestered in the abundance of adipose tissue in metabolic
syndrome, with decreased circulating levels [30]. Vitamin
D deﬁciency in obese patients is further increased due to
decreased sun exposure because of reduced mobility and
wearing clothing that covers most areas of skin because of
cosmetic preference. Vitamin D reduces inﬂammation by
modulating the expression of several cytokine genes [31].
Tzotzas and colleagues [32] reported rising serum vitamin D
levels after weight loss in obese women. Chui and colleagues
[33] found that subjects with hypovitaminosis have a higher
risk of insulin resistance and metabolic syndrome. Alvarez
and Ashraf [34] found in their meta-analysis of both cross-
sectional and prospective studies that vitamin D insuﬃ-
ciency (20–29ng/ml) and deﬁciency (less than 20ng/ml)
have direct and indirect eﬀects on insulin secretion and
insulin action. Maki and colleagues [35]f o u n dt h a ts e r u m
triglycerides, waist circumference, and body mass index is
inversely related to vitamin D levels. They showed that the
prevalence of metabolic syndrome is inversely proportional
to serum vitamin D levels, suggesting that there is a link
between metabolic syndrome and lower vitamin D levels.
Future studies need to be performed to assess controlled
supplementationof vitamin D and its eﬀectson components
of metabolic syndrome [36].
In addition, low vitamin D levels have recently been
associated with an increased incidence of cardiovascular
events[37, 38].
8.Conclusion
In conclusion, metabolic syndrome and psoriasis are closely
related and share common genetic and inﬂammatory com-
ponents. As discussed above there has been recent research
suggesting vitamin D plays a role in metabolic syndrome
and improves psoriatic skin lesions. We propose that there is
meritinperforminglarge-scaleclinicaltrials aimedatrevisit-
ing the use of oral vitamin D todirectly target manifestations
of psoriasis and metabolic syndrome at the same time. On
application to psoriasis management and prognosis, the use
of oral vitamin D has great potential in clearing psoriatic
skin lesions and at the same time also decreasing the risk for
cardiovascular disease and decreasing disease morbidity and
mortality. Randomized, blinded, large-scale, and long-term
clinical studies are needed to address this important issue.
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